The VPT Patient Safety Trial (VPS) for Serious Infections
This study, called The VPT Patient Safety Trial (VPS), is comparing two common antibiotic combinations for patients in the hospital with serious infections. You might be eligible if you are 18 or older, hospitalized, and your doctor is considering either vancomycin with piperacillin/tazobactam or vancomycin with meropenem for your infection. The study aims to find out if the combination of vancomycin and piperacillin/tazobactam causes kidney problems (acute kidney injury or AKI) more often than other combinations. Doctors want to know which antibiotic combination is safer for your kidneys. The main way they will measure this is by checking a kidney marker called serum cystatin C (Scys) after 7 days.
- Study design
- This is an interventional study enrolling 852 participants. It compares two different antibiotic dosing strategies.
- What's involved
- Not specified in the trial record.
- Compensation
- Not stated in the trial record.
- Follow-up
- Your kidney health will be checked for 7 days after starting treatment.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
The Vancomycin Piperacillin/Tazobactam (VPT) Patient Safety Trial (VPS)
At a glance
Conditions
Where it's being run
3 sites across 3 statesStudy leadership
- Daniel Freilich, MD · PRINCIPAL_INVESTIGATOR · Bassett Medical Center
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
What this trial measures
- Serum cystatin C (Scys)7 days
Difference between highest Scys (mg/L) post-treatment over 7 days minus Scys pre-treatment, expressed as ratio of pre-treatment level